Neutrolis Expands Senior Leadership Team to Drive Development of Growing Pipeline of Non-Immunosuppressive Therapies for NET-mediated Autoimmune Diseases [Yahoo! Finance]
Coherus BioSciences, Inc. (CHRS)
Last coherus biosciences, inc. earnings: 2/27 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.coherus.com
Company Research
Source: Yahoo! Finance
CAMBRIDGE, Mass., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Neutrolis Inc., a clinical stage biotech company focused on targeting Neutrophil Extracellular Traps (NETs) for the treatment of autoimmune and inflammatory diseases, today announced the expansion of its senior leadership team to support advancement of the company's growing clinical pipeline and the next phase of its growth. Michael Fleming has been appointed as chief business and strategy officer, Andreas Reiff, M.D., joins Neutrolis as chief medical officer and Ralph Lambalot, Ph.D. as chief technology officer. “The expansion of our senior leadership team with the appointment of industry veterans Michael, Andreas and Ralph adds significant strategic and operational experience in business development, commercialization and clinical development, and research and technical operations,” said Toby Fox, Ph.D., co-founder and chief executive officer of Neutrolis. “Our new team members share our passion and vision of fulfilling the unme
Show less
Read more
Impact Snapshot
Event Time:
CHRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CHRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CHRS alerts
High impacting Coherus BioSciences, Inc. news events
Weekly update
A roundup of the hottest topics
CHRS
News
- Yahoo Finance [Yahoo! Finance]Yahoo! Finance
- Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 [Yahoo! Finance]Yahoo! Finance
- Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025GlobeNewswire
- Coherus BioSciences, Inc. (NASDAQ: CHRS) had its price target raised by analysts at Robert W. Baird from $4.00 to $6.00. They now have an "outperform" rating on the stock.MarketBeat
- Coherus BioSciences, Inc. (NASDAQ: CHRS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.MarketBeat
CHRS
Earnings
- 11/6/24 - Beat
CHRS
Sec Filings
- 12/17/24 - Form 4
- 12/4/24 - Form 8-K
- 12/4/24 - Form DEFA14A
- CHRS's page on the SEC website